SCHEMBL3650109

SCHEMBL3650109

CC(=O)Nc1cccc(Oc2ccc(Cl)nc2)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 10/20 0.57
KCNQ3 O43525 2/20 0.53
KCNQ2 O43526 2/20 0.53
KCNE1 P15382 1/20 0.53
KCNQ1 P51787 1/20 0.53
MTNR1A P48039 1/20 0.52
MTNR1B P49286 1/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PIP4K2A P48426 1/20 0.50
PIP4K2B P78356 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14384401 0.82 MTNR1A (0.62) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL14338249 0.81 MTNR1B (0.69) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL3654842 0.81 CDK8 (0.52) CDK8MTNR1AMTNR1BNPC1RAB9A
SCHEMBL14384402 0.81 MTNR1A (0.57) CDK8MTNR1AMTNR1BNPC1RAB9A
SCHEMBL9162294 0.80 MTNR1B (0.77) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL12888865 0.78 MAPK1 (0.65) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL2845250 0.77 MTNR1A (0.64) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL14384856 0.77 MTNR1A (0.64) CDK8MTNR1AMTNR1BNPC1RAB9A
SCHEMBL14384846 0.77 MTNR1A (0.64) CDK8MTNR1AMTNR1BNPC1RAB9A
SCHEMBL1122429 0.77 NTRK1 (0.67) NPC1RAB9ASMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-11-25 US disclosed
EP-2205317-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2010-07-14 EP disclosed
WO-2009044160-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298325-A1 PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HCRTR1, HCRTR2, RTN3 CDK8 1652/4885KCNQ3 1846/4885KCNQ2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.